Results of prospective clinical trials on adult Ph-ALL according to MRD response. (A) Results of the NILG ALL 09/00 trial (with kind permission by Dr R. Bassan, Bergamo, Italy).^91,97  Disease-free survival according to MRD levels at weeks 16 and 22. MRD^neg, negative or low MRD positivity (10⁻⁴) at week 16 and no detectable MRD at week 22; MRD^pos, all other patients with evaluable MRD results; MRD^u/k, MRD risk class unknown. (B) Results of the GMALL 06/99 and 07/03 trials (with kind permission by N. Gökbuget, Frankfurt, Germany).⁶  Probability of continuous complete remission according to MRD at week 16 in SR and HR patients. MolCR, MRD negativity with an assay sensitivity of ≥10⁻⁴; MolFail, quantifiable MRD positivity ≥10⁻⁴. (C) Results of the PETHEMA ALL-AR-03 trial (with kind permission by J. Ribera, Barcelona, Spain).⁷  Disease-free survival for HR patients by intention to treat. Assignment to postconsolidation therapy according to early cytomorphologic response and postconsolidation flow-MRD (weeks 16-18): assignment to chemotherapy if <10% blasts in bone marrow (day 14) and flow MRD <5 × 10⁻⁴ (weeks 16-18); assignment to allo-HSCT if ≥10% blasts in BM (day 14) and/or flow MRD ≥ 5 × 10⁻⁴ (weeks 16-18). (D) Results of the GRAALL-2003/2005 trials (with kind permission by H. Dombret, Paris, France).⁹³  Simon-Makuch plots of SCT time-dependent analysis of RFS according to MRD at week 6 and type of postremission treatment (SCT vs no SCT) in HR Ph-negative ALL.